Last Updated : May 2, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Spriafil | Posaconazole | Aspergillus and Candida infections | Do not list | Complete | ||
| Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Intrarosa | prasterone | Postmenopausal vulvovaginal atrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
| Effient | Prasugrel hydrochloride | Acute Coronary Syndrome | Do not list | Complete | ||
| Lyrica | Pregabalin | diabetic peripheral neuropathy | Do not list | Complete | ||
| Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | ||
| Mictoryl | Propiverine hydrochloride | Overactive bladder (OAB) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Hemangiol | Propranolol | Infantile hemangioma | Withdrawn |
Last Updated : May 2, 2024